Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis

Last updated: October 27, 2023
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sarcoidosis

Lung Disease

Treatment

N/A

Clinical Study ID

NCT06113991
APHP230386
  • Ages > 18
  • All Genders

Study Summary

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood. The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years
  • Sufficiently documented medical record.
  • Informed patients who did not object to participating in the research, or for deceasedpatients, did not object to the use of their data.
  • Cases: Patients followed for confirmed chronic beryllium disease by expert teams basedon the ATS 2014 criteria, i.e., a history of exposure to beryllium, positivity of twoabnormal lymphocyte proliferation tests (LPT) in blood and/or an abnormal LPT inbronchoalveolar lavage, granuloma found in pulmonary biopsy associated by compatibleclinical, radiological or spirometric abnormalities.
  • Controls: Patients followed for sarcoidosis according to the ATS/ERS/WASOG criteria,i.e., (i) a compatible presentation, (ii) the presence of non-necrotizinggranulomatosis in one or more tissues (except Löfgren's syndrome or Heerfordtsyndrome), (iii) and exclusion of alternative causes of granulomatous diseases withpulmonary parenchymal involvement on thoracic CT and/or chest radiography.
  • Controls: without occupational exposure to beryllium.

Exclusion

Exclusion Criteria:

  • Patients under trustee.

Study Design

Total Participants: 200
Study Start date:
June 14, 2023
Estimated Completion Date:
December 14, 2023

Study Description

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood . The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

Connect with a study center

  • 001 - Service Pneumologie

    Bobigny, Avicenne
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.